7 July 2026 in Journal of Radiological Protection
Despite the increased use of 177 Lu in nuclear medicine (NM) over the last 10 years, the knowledge of the actual exposure of the extremities due to manipulation of this pharmaceutical is limited. The purpose of this study is to assess the extremity dose during the preparation and administration of 177 Lu-labelled radiopharmaceuticals in a wide range of NM practices. Workers in 10 NM centres throughout Europe wore a ring dosimeter on the base of the index finger of the non-dominant hand during preparation and/or administration of 177 Lu-labelled radiopharmaceuticals. Information on manipulated activity, tasks performed and protection measures was collected to allow sub-analyses. The median ring dose per monitoring interval was 0.16 mSv, with a maximum of 2.27 mSv in one month. The median normalised dose amounted 3.5 µ Sv GBq −1 (range 0.5–525). The highest monthly doses were found for workers involved in preparation of the pharmaceutical. The workers performing manual administrations (6.5 µ Sv GBq −1 ) showed higher normalised ring doses than those using the gravity method (3.5 µ Sv GBq −1 ) or a syringe pump (1.0 µ Sv GBq −1 ). Explanations for the wide range of normalised ring doses may be found in the different techniques applied in this study and the differences in minimum reportable doses of the dosimeters. When the data is extrapolated using a fingertip to ring dose ratio of 5, an annual fingertip dose of 1–136 mSv is found, with a median fingertip dose of 10 mSv per year. Extremity exposure during 177 Lu handling remained well below dose limits. The highest normalised doses occurred during preparation and manual administration. Overall, this investigation shows doses remain low when appropriate radiation protection measures (e.g. shielding and minimising time at short distance) are being applied.
25 June 2026 in Journal of Radiological Protection
In low-energy photon fields, such as those encountered during fluoroscopy-guided interventions, the current operational quantity for area dosimetry, ambient dose equivalent H*(10), overestimates effective dose by roughly a factor of two. ICRU Report 95 introduces a revised set of operational quantities intended to better align with protection quantities, replacing H*(10) with ambient dose H* for area monitoring. Experimental data validating these changes in realistic clinical environments remain scarce. This study examines the differences between current and newly proposed operational quantities in scattered radiation fields representative of occupational staff exposure during fluoroscopy-guided procedures. Measurements were performed using a Timepix4 hybrid pixel detector operated simultaneously as an X-ray spectrometer and dosimeter. The detector provides energy-resolved photon fluence measurements convertible into operational dose quantities via published fluence-to-dose conversion coefficients. Measurement campaigns were conducted in a urology theatre and an interventional cardiology (IC) theatre under realistic clinical conditions. Photon spectra were recorded at staff positions representative of standard procedures and converted into current and newly proposed quantities relevant to whole-body, skin, and eye lens exposure. The influence of beam angulation and additional shielding was further investigated in the IC theatre.For whole-body exposure, ratios between H* and H*(10) ranged from 0.52 in urology to 0.59 in IC. Quantities relevant to skin and eye lens exposure remained close to unity, with deviations not exceeding 5% and 8%, respectively. Beam angulation and shielding induced only minor variations in these ratios, below 5%.These results provide the first experimental validation of ICRU Report 95 quantities in interventional workplaces. Whole-body dosimetry is most affected by the transition, while skin and eye lens monitoring should remain largely unchanged. Ambient dosimeters calibrated in H*(10) used in low-energy photon fields may be recalibrated using a single procedure-specific calibration factor, whereas calibration procedures for skin and eye lens dosimeters may remain unchanged.